Found 219 articles
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
Takeda announced strong financial results for fiscal year 2022, delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products.
Dr. Reddy’s Q4 & FY23 Financial Results
Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023.
Schrödinger Reports Strong First Quarter 2023 Financial Results
Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the first quarter ended March 31, 2023.
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2023, which reflect robust in-line and new product portfolio growth, strong commercial execution and continued advancement of the product pipeline.
Takeda will advance its experimental drug for plaque psoriasis, TAK-279, to Phase III later this year after the TYK2 inhibitor met its primary and secondary endpoints in a Phase IIb study.
Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting
Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans.
Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.
Ajax Therapeutics Appoints Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development
Ajax Therapeutics, Inc. today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.
Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results
Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided its financial outlook for 2023.
Spanish drugmaker Grifols announced a comprehensive plan Wednesday to improve its efficiency and cost-effectiveness – a move that will reportedly cost some 2,000 U.S. jobs.
Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of an $111.3 million cash distribution from Nimbus Therapeutics, LLC (Nimbus) in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858.
Nimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 Subsidiary
Nimbus Therapeutics, LLC announced the closing of Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 inhibitor program, which includes the oral, selective allosteric TYK2 inhibitor NDI-034858, now known as TAK-279.
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST), as set forth in the share purchase agreement, following clearance from the United States Federal Trade Commission and a satisfaction of other closing conditions.
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
Takeda announced financial results for the third quarter of fiscal year 2022.
Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.
Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities
Schrödinge , Inc. today provided an update on its progress across the business and announced its strategic priorities for 2023.
Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
On the heels of positive Phase IIb data in plaque psoriasis, Takeda is acquiring both the therapy and Nimbus Lakshmi, a wholly owned subsidiary, in a potentially $6 billion deal.
Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
Nimbus Therapeutics today announced that it has signed a definitive agreement under which Takeda (TSE:4502/NYSE:TAK) will acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858.
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis.